CB2 Receptor Modulators for Selective Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively manage all types of nociceptive and neuropathic pain, and existing treatments for immune and inflammatory disorders lack specificity and efficacy, particularly due to adverse side effects associated with CB1 receptor activation.
Innovation Solution
Development of novel CB2 receptor modulators, specifically compounds of formula (I) and their pharmaceutical compositions, which selectively target CB2 receptors to treat pain and inflammatory disorders without activating CB1 receptors, thereby offering a unique pharmacotherapy for pain management and immunomodulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective CB agonists are used to treat pain, then analgesic effects are achieved, but adverse side effects occur due to CB1 receptor activation
Solution Approach 1:
The invention segments the cannabinoid receptor targeting by developing compounds that selectively bind to CB2 receptors while avoiding CB1 receptors. This segmentation allows the analgesic effects to be achieved through CB2 activation without the adverse side effects associated with CB1 activation, effectively dividing the receptor target landscape to isolate beneficial effects from harmful ones.
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (formula I) that are tailored to interact preferentially with CB2 receptors in specific tissues (immune cells, peripheral tissues) while having minimal affinity for CB1 receptors in the central nervous system. This localized selectivity ensures that therapeutic effects are produced at the target site without affecting distant systems.
2Reliability
If CB1 receptor activation is used for pain management, then central analgesic effects are achieved, but psychotropic side effects occur
Solution Approach 1:
The invention extracts the analgesic function from the CB1 receptor pathway and relocates it to the CB2 receptor pathway. By developing compounds that selectively activate CB2 receptors, the invention removes the psychotropic side effects associated with CB1 activation while retaining and potentially enhancing analgesic efficacy through peripheral and immune system modulation.
3Adaptability or versatility
If existing pain therapies are used, then some pain types are treated, but effectiveness is limited across all nociceptive and neuropathic pain states
Solution Approach 1:
The invention creates universal CB2 receptor modulators that can address multiple types of pain (nociceptive and neuropathic) through a single mechanism of action. The compounds of formula I are designed to interact with CB2 receptors across different tissue types and pain pathways, providing broad-spectrum analgesic coverage that overcomes the limitations of existing therapies targeted at specific pain conditions.
Data Source
AI summary
Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1 and Rx are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.